Advertisement

Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety

  • Yosuke Inoue
  • Akio Saiura
  • Atsushi Oba
  • Shoji Kawakatsu
  • Yoshihiro Ono
  • Takafumi Sato
  • Yoshihiro Mise
  • Takeaki Ishizawa
  • Yu Takahashi
  • Hiromichi Ito
Original Article

Abstract

Background

We describe the short- and long-term outcomes for PDAC patients after tailored mesopancreas dissection using supracolic artery-first approach followed by adjuvant therapy.

Methods

This study analyzed 233 consecutive patients who underwent artery-first pancreaticoduodenectomy for PDAC. Dissection extent for the superior mesenteric artery (SMA) was categorized into three levels: level 2 (LV2) including regional lymph nodes, level 3 (LV3) with hemicircumferential nerve plexus dissection, and extended-level 3 (E-LV3) including borderline resectable cases for the SMA. All clinical, pathological, and survival outcomes were reviewed.

Results

LV2/3/E-LV3 dissection was performed in 77/115/41 patients. The short-term outcomes were similar among groups without mortality. Although postoperative diarrhea requiring opioids was significantly more frequent in the E-LV3 group (76%) than other groups (vs. LV2 (21%), P < .0001; vs. LV3 (34%), P < .0001; LV2 vs. LV3, P = 0.20), most cases of diarrhea were well controlled. Adjuvant chemotherapy was introduced similarly among groups (LV2, 76%; LV3, 81%; E-LV3, 88%, P = 0.29). The 3- and 5-year overall survival rates in the LV2/3/E-LV3 groups were 42/33/42% and 27/22/26%, respectively, showing no significant difference among groups.

Discussion

Our tailored dissection and preemptive use of opioid antidiarrheal effectively prevents intractable diarrhea, increasing the success of adjuvant chemotherapy.

Keywords

Pancreaticoduodenectomy Artery first Superior mesenteric artery Diarrhea Adjuvant therapy 

Abbreviations

PD

pancreaticoduodenectomy

SMA

superior mesenteric artery

PDAC

pancreatic ductal adenocarcinoma

plSMA

the nerve plexus around the SMA

LN

lymph node

LV2

level 2

LV3

level 3

BR

borderline resectable

E-LV3

extended-level 3

AC

adjuvant chemotherapy

PV

portal vein

HA

hepatic artery

POPF

postoperative pancreatic fistula

DGE

delayed gastric emptying

Notes

Acknowledgments

We thank Mr. Koki Tazoe (a free graphic designer, Nerima-ku, Tokyo) for the valuable edition of digital illustration as schemata in the article.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Whipple AO, Parsons WB, Mullins CR. Treatment of Carcinoma of the Ampulla of Vater. Ann Surg. 1935;102(4):763–79.CrossRefGoogle Scholar
  2. 2.
    Hackert T, Werner J, Weitz J, Schmidt J, Buchler MW. Uncinate process first--a novel approach for pancreatic head resection. Langenbeck's Arch Surg. 2010;395(8):1161–4.CrossRefGoogle Scholar
  3. 3.
    Nakao A, Takagi H. Isolated pancreatectomy for pancreatic head carcinoma using catheter bypass of the portal vein. Hepato-Gastroenterology. 1993;40(5):426–9.PubMedGoogle Scholar
  4. 4.
    Weitz J, Rahbari N, Koch M, Buchler MW. The "artery first" approach for resection of pancreatic head cancer. J Am Coll Surg. 2010;210(2):e1–4.CrossRefGoogle Scholar
  5. 5.
    Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J et al. Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. Ann Surg. 2015;262(6):1092–101.CrossRefGoogle Scholar
  6. 6.
    Inoue Y, Saiura A, Tanaka M, Matsumura M, Takeda Y, Mise Y et al. Technical Details of an Anterior Approach to the Superior Mesenteric Artery During Pancreaticoduodenectomy. J Gastrointest Surg. 2016;20(10):1769–77.CrossRefGoogle Scholar
  7. 7.
    Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23(4):1044–52.CrossRefGoogle Scholar
  8. 8.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefGoogle Scholar
  9. 9.
    Kimura W. Strategies for the treatment of invasive ductal carcinoma of the pancreas and how to achieve zero mortality for pancreaticoduodenectomy. J Hepato-Biliary-Pancreat Surg. 2008;15(3):270–7.CrossRefGoogle Scholar
  10. 10.
    Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19(3):230–41.CrossRefGoogle Scholar
  11. 11.
    Japan pancreas Society. General Rules for the Study of Pancreatic Cancer ( The 7th Edition). 2016.Google Scholar
  12. 12.
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57. doi: https://doi.org/10.1016/s0140-6736(16)30583-9.CrossRefPubMedGoogle Scholar
  13. 13.
    Network NCC. Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. 2015.Google Scholar
  14. 14.
    Verbeke CS. Operative specimen handling an evaluation of resection margins. In: Kim SW, Yamaue H, eds Pancreatic cancer with special focus on topical issues and surgical techniques Heiderberg: Springer. 2017:67–87.Google Scholar
  15. 15.
    Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161(3):584–91.CrossRefGoogle Scholar
  16. 16.
    Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761–8.CrossRefGoogle Scholar
  17. 17.
    Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRefGoogle Scholar
  18. 18.
    Chandrasegaram MD, Goldstein D, Simes J, Gebski V, Kench JG, Gill AJ et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015;102(12):1459–72.CrossRefGoogle Scholar
  19. 19.
    Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27(17):2855–62.CrossRefGoogle Scholar
  20. 20.
    Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010;251(6):1003–10.CrossRefGoogle Scholar
  21. 21.
    Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7.CrossRefGoogle Scholar
  22. 22.
    Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C et al. Pancreatic Cancer Surgery: The New R-status Counts. Ann Surg. 2017;265(3):565–73.CrossRefGoogle Scholar
  23. 23.
    Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F et al. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Ann Surg. 2017;266(5):787–96.CrossRefGoogle Scholar
  24. 24.
    Farnell MB, Pearson RK, Sarr MG, Di Magno EP, Burgart LJ, Dahl TR et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–28; discussion 28–30.  https://doi.org/10.1016/j.surg.2005.06.044.CrossRefPubMedGoogle Scholar
  25. 25.
    Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999;229(5):613–22.CrossRefGoogle Scholar
  26. 26.
    Nguyen TC, Sohn TA, Cameron JL, Lillemoe KD, Campbell KA, Coleman J et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg. 2003;7(1):1–9;CrossRefGoogle Scholar
  27. 27.
    Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;267(5):936–945.Google Scholar
  28. 28.
    Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y et al. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement. Pancreas. 2016;45(10):1438–46.CrossRefGoogle Scholar
  29. 29.
    Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas. 2013;42(6):1004–10.CrossRefGoogle Scholar
  30. 30.
    Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006;13(9):1189–200.CrossRefGoogle Scholar
  31. 31.
    Strobel O, Hinz U, Gluth A, Hank T, Hackert T, Bergmann F et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann Surg. 2015;261(5):961–9.CrossRefGoogle Scholar
  32. 32.
    Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17(2):257–66.CrossRefGoogle Scholar
  33. 33.
    Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591–600.CrossRefGoogle Scholar
  34. 34.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.CrossRefGoogle Scholar
  35. 35.
    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.CrossRefGoogle Scholar
  36. 36.
    Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12.CrossRefGoogle Scholar
  37. 37.
    Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014;259(4):656–64.CrossRefGoogle Scholar
  38. 38.
    Satoi S, Yanagimoto H, Yamamoto T, Ohe C, Miyasaka C, Uemura Y et al. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Surg Today. 2017;47(1):84–91.CrossRefGoogle Scholar
  39. 39.
    Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer. 2010;116(12):2932–40.CrossRefGoogle Scholar
  40. 40.
    Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21(9):2873–81.CrossRefGoogle Scholar
  41. 41.
    Bakens MJ, van der Geest LG, van Putten M, van Laarhoven HW, Creemers GJ, Besselink MG et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 2016;5(10):2825–31.CrossRefGoogle Scholar
  42. 42.
    Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM et al. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches?. Ann Surg. 2014;260(4):633–8.CrossRefGoogle Scholar
  43. 43.
    Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88.CrossRefGoogle Scholar
  44. 44.
    Takahashi H, Akita H, Tomokuni A, Kobayashi S, Ohigashi H, Fijiwara Y et al. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence. Ann Surg. 2016;264(6):1091–7.CrossRefGoogle Scholar
  45. 45.
    Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg. 2016;264(3):457–63.CrossRefGoogle Scholar
  46. 46.
    Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.CrossRefGoogle Scholar
  47. 47.
    Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6(6):1201–19.CrossRefGoogle Scholar
  48. 48.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefGoogle Scholar
  49. 49.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRefGoogle Scholar
  50. 50.
    Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2018

Authors and Affiliations

  • Yosuke Inoue
    • 1
  • Akio Saiura
    • 1
  • Atsushi Oba
    • 1
  • Shoji Kawakatsu
    • 1
  • Yoshihiro Ono
    • 1
  • Takafumi Sato
    • 1
  • Yoshihiro Mise
    • 1
  • Takeaki Ishizawa
    • 1
  • Yu Takahashi
    • 1
  • Hiromichi Ito
    • 1
  1. 1.Department of Gastrointestinal SurgeryCancer Institute Hospital, Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations